

ASSIGNMENT OF INVENTION

WHEREAS, we, MARGO P. COHEN and REX S. CLEMENTS, residing at 115 Central Park West, New York, New York 10023 and P.O. Box 343, 1036 Durham Road, Pineville, PA 18946, respectively, have made a certain new and useful invention in IN VIVO METHODS OF TREATMENT TO PREVENT KIDNEY DYSFUNCTION USING SUBSTANCES THAT INHIBIT ALBUMIN GLYCATION, filed on January 29, 1998.

WHEREAS, We MARGO P. COHEN and REX S. CLEMENTS both are employees of EXOCELL, INC..

WHEREAS, EXOCELL, INC., a corporation organized and existing under the laws of the Commonwealth of Pennsylvania and having place of business at 3508 Market Street, Suite 420, Philadelphia, PA 19104 is desirous of acquiring the entire right, title and interest in and to the invention and all improvements thereon which may be made, conceived or acquired by us during the course of our association with EXOCELL, INC., aforesaid and for one year thereafter, in and throughout the United States, its territories and all countries foreign thereto, and in and to said application for Letters Patent and in and to any and all Letters Patent of the United States and all countries foreign thereto which have been granted or may be granted on said invention or any part thereof, or any improvements thereon.

NOW, THEREFORE IN CONSIDERATION of the sum of One Dollar (\$1.00), and other goods and valuable consideration, the receipt of which is hereby acknowledged, we, MARGO P. COHEN and REX CLEMENTS, by these presents do sell, assign and transfer unto the EXOCELL, INC., aforesaid our entire right, title and interest in and throughout the United States, its territories and all countries foreign thereto in and to said invention and any improvements thereon which may

be made, conceived or acquired by us during the course of our association with the EXOCELL, INC., and for one year thereafter, in and to said application for Letters Patent and any and all Letters Patent and extensions thereof, of the United States and countries foreign thereto which have been or may be granted on said invention or any part thereof, or improvements thereon or on said application, or any divisional, continuing, renewal, reissue, or other application and all international priority rights associated therewith, based in whole or in part thereon, or based upon said invention, or any improvements thereon;

TO BE HELD AND ENJOYED by EXOCELL, INC., and its legal representatives and assigns to the full ends of the terms for which said Letters Patent, or any of them, have granted as fully and entirely as the same would have been held and enjoyed by us had no sale and assignment of said interest been made; and we do hereby authorize and request the Commissioner of Patent and Trademarks to issue any and all Letters Patent which may be granted upon the application above referred to, or any of them, or upon said invention or any part thereof, or upon any improvements thereon which may be made, conceived or acquired by us during the course of our association with the same company and for one year thereafter, to EXOCELL, INC., aforesaid, and we hereby agree for ourselves, our heirs, executors and administrators, to execute without further consideration, any further legal documents and any further assignments and any releases, reissues, renewal or other application for Letters Patent that may be deemed necessary by the Assignee herein named, fully to secure to the Assignee its interest as aforesaid in and to said invention or any part thereof or any improvements thereon, and in and to said several Letters Patent, or any of them.

We do hereby covenant for ourselves and our legal representatives, and agree with EXOCELL, INC., and its legal representatives, that we have granted no license to make or sell the said invention, that prior to the execution of this deed our right, title and interest in the invention has

CERTIFICATE

This is to certify that the application above referred to for an invention in IN VIVO METHODS OF TREATMENT TO PREVENT KIDNEY DYSFUNCTION USING SUBSTANCES THAT INHIBIT ALBUMIN GLYCATION, was filed in the United States Patent and Trademark Office on the January 29, 1998 and assigned Serial No. 09/015,148.

IN WITNESS WHEREOF, I hereunto affix my hand and seal this 6th day of April, 1998.



Robert S. Silver